An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron.

Trial Profile

An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2013

At a glance

  • Drugs Granisetron (Primary)
  • Indications Nausea and vomiting
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Jul 2013 Outcomes for part 2 of this trial presented at the Multinational Association for Supportive Care in Cancer (MASCC) 2013 Annual Meeting, according to a ProStrakan media release.
    • 08 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Oct 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top